“EUnetHTA Early Dialogues aim at helping pharmaceutical and MedTech companies to understand the evidence and information needs of the HTA organisations and reimbursement bodies across Europe in order to inform decisions on coverage of newly developed health technologies. The goal is to improve the quality and adequacy of early evidence generation in order to be useful for the HTA process of reviewing and synthesising evidence to inform coverage decisions.”As part of this work programme, EUNetHTA published its “Consolidated Procedure For Early Dialogues”. It’s available here. The procedure is too specific, but the templates may be a useful starting point.
Wednesday, 11 May 2016
Improving evidence generation for reimbursement